ADORA2B and serous adenocarcinoma: In contrast, for serous carcinoma, the surveillance of both cohorts (482 with low expression vs. 622 with high expression) revealed that the group with reduced ADORA2B had a worse prognosis than the group with high ADORA2B levels (15.80 months vs. 18.60 months, respectively) (p = 0.015) (Figure 1B).